Primary hyperoxaluria type 1 (PH1) is a rare, inherited metabolic disorder caused by a deficiency of the enzyme alanine-glyoxylate aminotransferase (AGT). The disorder results in excessive production of oxalate in the body, which can lead to the formation of oxalate kidney stones, nephrocalcinosis, and eventually chronic renal failure. PH1 usually presents in childhood, but symptoms can vary depending on the severity of the disease and the involvement of different organ systems. Pathological changes occur due to the accumulation of oxalate and its salts, which leads to damage to the kidneys and other organs, including the liver and heart.
History of the disease and interesting historical facts
Primary hyperoxaluria was first described in 1962 by scientists LD Robinson and RC Bock, when data on patients with recurrent kidney stones and signs of renal failure began to appear in the medical literature. In the following decades, cases of familial transmission of the disease were observed, which made it possible to establish its hereditary nature. In 1992, the gene-molecular mechanism of inheritance was identified, and mutations in the AGXT gene were discovered, which became the basis for further research and understanding of the pathogenesis of the disease. Research in recent years has shown that optimization of diagnostic and therapeutic approaches can significantly improve the prognosis for patients with PG-1.
Epidemiology
PG-1 is a rare disorder that occurs in various populations. Population studies estimate its prevalence to be 1 in 100,000 live births. In some ethnic groups, such as Arabs and Jews, the prevalence may be as high as 1 in 30,000. A study of over 500 cases of PG-1 showed that most people first develop the disease before the age of 5, highlighting the importance of early diagnosis and treatment to reduce the risk of kidney failure.
Genetic predisposition to this disease
The genetic basis of primary hyperoxaluria type 1 is mutations in the AGXT gene, located on chromosome 2q36. This gene encodes the enzyme AGT, which is involved in the metabolism of glycolate and alanine. The most common mutations include nucleotide substitutions and deletions that result in decreased enzyme activity or its complete loss. This results in the accumulation of glycolate and, as a consequence, the formation of oxalate. Carriage of mutations in AGXT occurs in an autosomal recessive manner, which means that both parents must be carriers for an affected child to be born.
Risk factors for the development of this disease
There are several risk factors that contribute to the development of primary hyperoxaluria type 1, which can be classified as follows:
- Genetic factors: family history of primary hyperoxaluria.
- Associated metabolic disorders: disorders of calcium and oxalate metabolism, which can provoke stone formation.
- Nutritional factors: High oxalate diets (eg, spinach, rhubarb, beets) may worsen symptoms in susceptible individuals.
It should also be taken into account that certain medications and exposure to environmental toxins may aggravate or provoke the development of the disease.
Diagnosis of this disease
Diagnosis of primary hyperoxaluria type 1 is based on clinical signs and laboratory tests. The main symptoms include:
- Recurrent renal colic
- Hemuria (blood in urine)
- Growth retardation and renal function degradation
Basic laboratory tests include:
- Urine tests for oxalate.
- Blood biochemistry test to assess kidney function.
To confirm the diagnosis, you may need:
- Ultrasound examination of the kidneys to detect stones and nephrocalcinosis.
- CT scan for detailed analysis of the kidneys.
Differential diagnosis is important to exclude other causes of kidney stones, including hypercalcemia and other hereditary diseases.
Treatment
Treatment of primary hyperoxaluria type 1 includes both conservative and surgical approaches. Conservative treatment is aimed at reducing the level of oxalate in the body and includes:
- Selecting a low oxalate diet.
- Increasing fluid intake to reduce urinary oxalate concentrations.
- Use of alkalizing drugs to reduce oxalate levels.
Pharmacological treatment may include drugs such as pyridoxine (vitamin B6), which in some cases may improve glycolate metabolism and reduce oxalate levels. In cases of severe renal failure, surgical intervention, including nephrectomy or renal transplantation, may be required.
List of medications used to treat this disease
The following drugs are currently available for the treatment of primary hyperoxaluria type 1:
- Pyridoxine (vitamin B6)
- Alkalizing agents such as sodium bicarbonate
- Drugs for controlling calcium and oxalate levels
Each of these drugs should be used after consultation with a doctor and according to the individual indications of the patient.
Disease monitoring
Monitoring of patients with primary hyperoxaluria type 1 includes regular follow-up examinations to assess renal function and urinary oxalate levels. The prognosis in the early stages of the disease can be favorable with adequate treatment and diet, but without proper monitoring, complications, including renal failure, are possible.
Complications may include:
- Irreversible kidney damage
- Urinary tract stones
- Increased risk of osteoporosis and other metabolic conditions
Age-related features of the disease
Primary hyperoxaluria type 1 can manifest at any age, but symptoms most often appear in childhood. In newborns and children under 5 years of age, the manifestations of the disease can be most severe, as kidney damage progresses rapidly. In adults, patients may suffer from complications associated with the long-term course of the disease, such as chronic renal failure or the need for hemodialysis.
Questions and Answers
- What are the main symptoms of primary hyperoxaluria type 1? The main symptoms include recurrent renal colic, haemouria, growth retardation and progressive renal failure.
- Is it possible to cure this disease? There is no complete cure for primary hyperoxaluria type 1, but with proper treatment and diet, symptoms can be controlled and the progression of the disease can be slowed.
- What diagnostic tests are used for primary hyperoxaluria type 1? Diagnostics include urine tests, blood biochemistry, ultrasound and computed tomography of the kidneys.
- How is primary hyperoxaluria type 1 treated? Treatment includes dietary changes, drug therapy, and in some cases surgery.
- What is the prognosis for patients with primary hyperoxaluria type 1? The prognosis varies, but with early diagnosis and proper treatment, quality of life can be significantly improved and the risk of complications can be reduced.
